By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad
Symbol: ARIA

Company News
Baxalta in Talks to Buy Ariad (ARIA) to Boost Oncology Biz 8/28/2015 3:33:39 PM
Battling Weak Stocks and Earnings Losses, Ariad (ARIA) Leases Almost Half of HQ to IBM (IBM) 8/24/2015 6:43:38 AM
Ariad (ARIA) Announces First Patient Treated In Phase 2 Dose-Ranging Optic Trial Of Iclusig (Ponatinib) 8/10/2015 10:03:13 AM
Ariad (ARIA) Reports Second Quarter 2015 Financial Results And Progress On Strategic Objectives 8/5/2015 11:59:31 AM
Four Boston Biotechs That Could Make M&A Moves This Year 7/30/2015 5:26:16 AM
PDL BioPharma (PDLI) to Infuse Up to $200 Million Into Troubled Ariad (ARIA) 7/29/2015 6:04:35 AM
Ariad (ARIA) To Webcast Conference Call On Second Quarter 2015 Financial Results 7/22/2015 10:02:40 AM
Ariad (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase II Pace Clinical Trial 6/12/2015 10:16:34 AM
Ariad (ARIA) And Paladin Labs Inc. (CC:PLB) Announce Commercial Distribution Agreement For Iclusig (Ponatinib) In Canada 6/10/2015 9:26:34 AM
Ariad (ARIA) To Present At The Goldman, Sachs & Co. Annual Global Healthcare Conference 6/8/2015 11:46:29 AM